Covalon's Markets

Covalon’s technology platforms are customizable for many medical device, consumer and veterinarian applications. We work closely with senior stakeholders in the pharmaceutical, medical device and diagnostic sectors to develop customized products that offer meaningful market advantages.

Covalon’s experience with both domestic and international organizations means that no major market, sector, or disease state falls outside of our capabilities or capacity. These include but are not limited to:

  • The advanced wound care market, estimated at $5 billion (U.S),  is projected to grow approximately 8% per year driven by increases in pressure and diabetic ulcers related to the growth of an aging population and the  increased prevalence of diabetes.  Covalon’s proprietary pro-active collagen technology serves this growing demand, and is customizable to create unique tissue repair products for the orthopaedic, neurological, dental, and ocular spaces.
  • The infection control market, which includes Healthcare Acquired Infections (HAI), is not only a growing healthcare issue, but a significant financial one as well. In the United States alone, the additional costs of HAIs are estimated to cost the system an additional $45 billion a year, and is therefore being aggressively targeted by all jurisdictions. Covalon’s proprietary infection control technology is a customized platform for coatings, vascular access, and wound care products.
  • The medical device coatings market, which is estimated by Global Industry Analytics to exceed $7.5 billion by the year 2015. Covalon’s proprietary technology delivers therapeutics, such as silver ions from medical device surfaces for extended periods of time thereby creating an antimicrobial or therapeutic surface coating. The coatings can be applied to silicone and latex catheters, peritoneal dialysis catheters, hemodialysis catheters, wound drains, central venous lines, orthopaedic metals and many other medical devices. Our proprietary coating can be formulated to provide controlled delivery of  various  therapeutics for a wide range of devices and is supported by an FDA device master file.